HPLC
IndustriesPharma & Biopharma
ManufacturerThermo Fisher Scientific
Significance of the Topic
Assessing impurities in active pharmaceutical ingredients is critical for ensuring drug safety, efficacy, and regulatory compliance. The European Pharmacopoeia method for quantifying Trimethoprim impurities H and I provides a standardized protocol to monitor trace-level contaminants that could impact product quality.
Study Objectives and Overview
The main goal of the study was to validate the European Pharmacopoeia (EP) 8.0 procedure for determining impurities H and I in Trimethoprim. The overview covers sample preparation, chromatographic conditions, system suitability assessment, and result interpretation under EP guidelines.
Methodology
The analytical procedure involves:
- Preparing a test solution by dissolving 25 mg of Trimethoprim in mobile phase and diluting to 25 mL.
- Preparing reference solution (a) by diluting 1 mL of test solution to 200 mL with mobile phase.
- Preparing reference solution (b) by dissolving 5 mg each of Trimethoprim and Impurity-B in mobile phase and diluting to 100 mL.
- Performing isocratic reversed-phase chromatography at 25 °C using a cyanopropyl column and phosphate buffer/methanol mobile phase at pH 3.1.
- Detecting analytes with UV at 280 nm over a 30-minute run time.
Used Instrumentation
The following instrumentation was employed:
- Liquid Chromatograph: UltiMate 3000 LC
- Column: Betasil-CN (4.6 × 250 mm, 5 µm)
- Detector: UV set to 280 nm
Main Results and Discussion
System suitability tests confirmed method performance:
- Resolution between Trimethoprim and Impurity B: criterion ≥ 2.0; obtained 5.9.
- Relative retention time (RRT) of Impurity H vs. Trimethoprim: expected ≈ 1.8; obtained 1.8.
Impurity I was not available at the time of analysis, so only Impurity H was assessed. The observed RRT for Impurity H met EP specifications, demonstrating method selectivity and precision.
Benefits and Practical Applications
This validated EP method enables pharmaceutical quality control laboratories to:
- Accurately quantify key impurities in Trimethoprim batches.
- Ensure compliance with pharmacopeial standards.
- Support stability studies by monitoring impurity profiles over time.
Future Trends and Potential Uses
Emerging directions include:
- Adoption of UHPLC formats to reduce run times and solvent consumption.
- Integration with mass spectrometric detection for enhanced impurity identification.
- Application of automated data analysis and machine learning for trend monitoring.
Conclusion
The EP-8.0 method for Trimethoprim impurities H and I has been successfully applied, meeting all system suitability criteria. Although Impurity I was unavailable, the validated procedure reliably detects Impurity H with high resolution and consistent retention time, ensuring robust impurity monitoring.
References
European Pharmacopoeia 8.0. Monograph for Trimethoprim Impurities Assay.
Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.